CD73 Inhibitor Oleclumab Plus Osimertinib in Previously Treated Patients With Advanced T790M-Negative EGFRm Non-Small-Cell Lung Cancer: A Brief Report

Publication history

Publication stage

Footnotes

Disclosures: Dong-Wan Kim has received travel/accommodation expenses from Amgen and Daiichi-Sankyo, and research grants/funding (to institution) from Alpha Biopharma, AstraZeneca, Boehringer Ingelheim, Bridge BioTherapeutics, Chong Keun Dang, Daiichi-Sankyo, GSK, Hanmi, Janssen, Merus, Mirati Therapeutics, MSD, Novartis, Ono Pharmaceutical, Pfizer, Roche/Genentech, Takeda, TP Therapeutics, Xcovery, and Yuhan. D. Ross Camidge has received personal fees from AstraZeneca. Catherine A. Shu reports consulting fees from Genentech, and advisory board participation for AstraZeneca, Genentech, Janssen, and Mirati. Kristen A. Marrone reports consultancy for Amgen and AstraZeneca, honoraria from Janssen, and advisory board participation for AstraZeneca, Mirati, and Puma. Xiuning Le reports consultancy for AbbVie, AstraZeneca, Boehringer Ingelheim, Eli Lilly, EMD Serono, Hengrui Therapeutics, Janssen, Novartis, and Spectrum, and has received research grants/funding (to institution) from Boehringer Ingelheim, Eli Lilly, EMD Serono, and Regeneron. Collin M. Blakely has received research grants/funding (to institution) from AstraZeneca, Mirati, Novartis, Spectrum, and Takeda, and reports advisory board participation for Janssen. Gee-Chen Chang has received honoraria from F. Hoffmann–La Roche Ltd, Eli Lilly and Company Oncology, AstraZeneca, Novartis, Pfizer, Boehringer-Ingelheim, Bristol Myers Squibb, and Merck Sharp & Dohme. Sandip Pravin Patel reports advisory board participation for AstraZeneca, Bristol Myers Squibb, Eli Lilly, Illumina, Paradigm, Rakuten, and Tempus, and has received research grants/funding (to institution) from AstraZeneca, Bristol Myers Squibb, Eli Lilly, Fate Therapeutics, Genocea, Incyte, Iovance, Merck, Pfizer, Roche/Genentech, and Xcovery. Gozde Kar, Zachary A. Cooper, Ramin Samadani, Michael Pluta, and Rakesh Kumar are full-time employees of and own stock in AstraZeneca. Suresh Ramalingam reports grants from AstraZeneca for this work and from Amgen, BMS, Merck, Genmab, Advaxis, Takeda, and GSK outside this work, plus consulting fees from Amgen, Genmab, BMS, AstraZeneca, GSK, and Merck. All remaining authors have declared no conflicts of interest.

CRediT authorship contribution statement:

Dong-Wan Kim: Investigation, Writing – Review & Editing. Sang-We Kim: Conceptualization, Methodology, Investigation, Writing – Review & Editing. D. Ross Camidge: Investigation, Resources, Data Curation, Writing – Review & Editing. Catherine A. Shu: Investigation, Writing – Review & Editing. Kristen A. Marrone: Investigation, Data Curation, Writing – Review & Editing. Xiuning Le: Investigation, Writing – Review & Editing. Collin M. Blakely: Investigation, Writing – Review & Editing. Keunchil Park: Conceptualization, Methodology, Validation, Formal analysis, Investigation, Resources, Data Curation, Writing – Original Draft, Writing – Review & Editing, Supervision. Gee-Chen Chang: Validation, Investigation, Data Curation, Writing – Review & Editing, Project Administration. Sandip Pravin Patel: Investigation, Writing – Original Draft, Writing – Review & Editing. Gozde Kar: Formal analysis, Writing – Review & Editing. Zachary A. Cooper: Conceptualization, Writing – Original Draft, Writing – Review & Editing. Ramin Samadani: Investigation, Data Curation, Writing – Review & Editing. Michael Pluta: Formal analysis, Writing – Review & Editing. Rakesh Kumar: Conceptualization, Writing – Review & Editing, Supervision, Project administration. Suresh Ramalingam: Conceptualization, Investigation, Writing – Review & Editing.

Identification

DOI: https://doi.org/10.1016/j.jtho.2022.12.021

Copyright

ScienceDirect